https://www.selleckchem.com/products/ipi-549.html
Incidence of grade≥3 thrombocytopenia decreased from 28% (month 1) to 9% and 5% (months 2 and 3, respectively), with protocol-directed dose interruptions and/or reductions. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) were reported in 2 and 6 niraparib-treated patients, respectively, and in 1 placebo patient each. Treatment discontinuations due to TEAEs were5% in each month and time interval measured. These data demonstrate the importance of appropriate dose reduction according to toxicity criteria and support the
Like
Comment
Share
